

**Attorney Docket Number:** MBIO1999-057CP2RCEM      **Serial Number:** 09/503,387

**CLAIM AMENDMENTS:**

1. (withdrawn) An isolated nucleic acid molecule selected from the group consisting of:
  - a) a nucleic acid molecule comprising a nucleotide sequence which is at least 45% identical to the nucleotide sequence of SEQ ID NO:1, 2, 14 or 15, the cDNA insert of the plasmid deposited with the ATCC as Accession Number 207180 or PTA-225, or a complement thereof;
  - b) a nucleic acid molecule comprising a fragment of at least 300 nucleotides of the nucleotide sequence of SEQ ID NO:1, 2, 14 or 15, the cDNA insert of the plasmid deposited with the ATCC as Accession Number 207180 or PTA-225, or a complement thereof;
  - c) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:3 or 16, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number 207180 or PTA-225; and
  - d) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:3 or 16, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number 207180 or PTA-225, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:3 or 16, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number 207180 or PTA-225.
2. (withdrawn) The isolated nucleic acid molecule of claim 1, which is selected from the group consisting of:
  - a) a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, 2, 14 or 15, the cDNA insert of the plasmid deposited with the ATCC as Accession Number 207180 or PTA-225, or a complement thereof; and
  - b) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:3 or 16, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number 207180 or PTA-225.

Attorney Docket Number: MBIO1999-057CP2RCEM Serial Number: 09/503,387

3. (withdrawn) The nucleic acid molecule of claim 1 further comprising vector nucleic acid sequences
4. (withdrawn) The nucleic acid molecule of claim 1 further comprising nucleic acid sequences encoding a heterologous polypeptide.
5. (withdrawn) A host cell which contains the nucleic acid molecule of claim 1.
6. (withdrawn) The host cell of claim 5 which is a mammalian host cell.
7. (withdrawn) A non-human mammalian host cell containing the nucleic acid molecule of claim 1.
8. (withdrawn) An isolated polypeptide selected from the group consisting of:
  - a) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:3 or 16, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:3 or 16;
  - b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:3 or 16, or the amino acid sequence encoded by the cDNA insert of plasmids deposited with the ATCC as Accession Number 207180 or PTA-225, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:2 or 15, or a complement thereof under stringent conditions; and
  - c) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 45% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:2 or 15, or at least 98% to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:2 or 15, or a complement thereof.
9. (withdrawn) The isolated polypeptide of claim 8 comprising the amino acid sequence of SEQ ID NO:3 or 16.

**Attorney Docket Number: MBIO1999-057CP2RCEM      Serial Number: 09/503,387**

10. (withdrawn) The polypeptide of claim 8 further comprising heterologous amino acid sequences.

11. (withdrawn) An antibody which selectively binds to a polypeptide of claim 8.

12. (withdrawn) The antibody of claim 11, wherein the antibody is a monoclonal antibody.

13. (withdrawn) A method for producing a polypeptide selected from the group consisting of:

a) a polypeptide comprising the amino acid sequence of SEQ ID NO:3 or 16, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number 207180 or PTA-225,

b) a polypeptide comprising a fragment of the amino acid sequence of SEQ ID NO:3 or 16, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number 207180 or PTA-225, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:3 or 16, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number 207180 or PTA-225; and

c) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:3 or 16, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number 207180 or PTA-225, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1 or 14, or a complement thereof under stringent conditions;

comprising culturing the host cell of claim 5 under conditions in which the nucleic acid molecule is expressed.

14. (withdrawn) A method for detecting the presence of a polypeptide of claim 8 in a sample, comprising:

(Page 5 of 25)

**Attorney Docket Number: MBIO1999-057CP2RCEM      Serial Number: 09/503,387**

a)      contacting the sample with a compound which selectively binds to a polypeptide of claim 8; and

b)      determining whether the compound binds to the polypeptide in the sample.

15. (withdrawn) The method of claim 14, wherein the compound which binds to the polypeptide is an antibody.

16. (withdrawn) A kit comprising a compound which selectively binds to a polypeptide of claim 8 and instructions for use.

17. (withdrawn) A method for detecting the presence of a nucleic acid molecule of claim 1 in a sample, comprising the steps of:

a)      contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule; and

b)      determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample.

18. (withdrawn) The method of claim 17, wherein the sample comprises mRNA molecules and is contacted with a nucleic acid probe.

19. (withdrawn) A kit comprising a compound which selectively hybridizes to a nucleic acid molecule of claim 1 and instructions for use.

20. (withdrawn) A method for identifying a compound which binds to a polypeptide of claim 8 comprising the steps of:

a)      contacting a polypeptide, or a cell expressing a polypeptide of claim 8 with a test compound; and

b)      determining whether the polypeptide binds to the test compound.

(Page 6 of 25)

**Attorney Docket Number: MBIO1999-057CP2RCEM      Serial Number: 09/503,387**

21. (withdrawn) The method of claim 20, wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of:

- a) detection of binding by direct detecting of test compound/polypeptide binding;
- b) detection of binding using a competition binding assay;
- c) detection of binding using an assay for TANGO 268-mediated signal transduction.

22. (withdrawn) A method for modulating the activity of a polypeptide of claim 8 comprising contacting a polypeptide or a cell expressing a polypeptide of claim 8 with a compound which binds to the polypeptide in a sufficient concentration to modulate the activity of the polypeptide.

23. (withdrawn) A method for identifying a compound which modulates the activity of a polypeptide of claim 8, comprising:

- a) contacting a polypeptide of claim 8 with a test compound; and
- b) determining the effect of the test compound on the activity of the polypeptide to thereby identify a compound which modulates the activity of the polypeptide.

24-25. (canceled)

26. (previously presented) A substantially purified non-human antibody or fragment thereof which specifically binds to a polypeptide of the amino acid sequence of SEQ ID NO:3, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207180.

27. (previously presented) A substantially purified non-human monoclonal antibody or fragment thereof which specifically binds to a polypeptide of the amino acid sequence of SEQ ID NO:3, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207180.

**Attorney Docket Number: MBIO1999-057CP2RCEM      Serial Number: 09/503.387**

28. (previously presented) The antibody of claim 27 which is a humanized antibody.

29. (previously presented) A monoclonal antibody or fragment thereof which specifically binds to a polypeptide of the amino acid sequence of SEQ ID NO:3, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207180.

30-32 (canceled)

33. (previously presented) A monoclonal antibody or fragment thereof which specifically binds to a polypeptide of the amino acid sequence of SEQ ID NO:3, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207180, which antibody is conjugated to a therapeutic moiety.

34. (previously presented) A monoclonal antibody or fragment thereof which specifically binds to a polypeptide of the amino acid sequence of SEQ ID NO:3, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207180, which antibody is linked to a detectable substance.

35. (previously presented) The antibody of claim 34, wherein the detectable substance is selected from the group consisting of an enzyme, a prosthetic group, a fluorescent material, a luminescent material, a bioluminescent material, and a radioactive material.

36. (previously presented) A substantially purified antibody or a fragment thereof which specifically binds to an extracellular domain of the amino acid sequence of SEQ ID NO:3, wherein said antibody or fragment does not contain more than 30% of contaminating antibodies directed against epitopes other than those on the TANGO 268 polypeptide.

**Attorney Docket Number: MBIO1999-057CP2RCEM      Serial Number: 09/503,387**

37. (amended) The antibody of claim 36, wherein the extracellular domain [comprises] consists of about amino acid residues 21 to 269 of SEQ ID NO:3.

38. (previously presented) The antibody of claim 36, wherein the extracellular domain comprises an immunoglobulin-like domain.

39. (amended) The antibody of claim 38, wherein the immunoglobulin-like domain [comprises] consists of about amino acid residues 48 to 88 or 134 to 180 of SEQ ID NO:3.

40. (previously presented) The antibody of claim 36 which is a polyclonal antibody.

41. (amended) [The antibody of claim 36 which is] A substantially purified antibody which specifically binds to an extracellular domain of the amino acid sequence of SEQ ID NO:3, wherein the antibody is a monoclonal antibody.

42. (amended) [The antibody of claim 36 which is] A substantially purified antibody which specifically binds to an extracellular domain of the amino acid sequence of SEQ ID NO:3, wherein the antibody is a chimeric antibody.

43. (amended) [The antibody of claim 36 which is] A substantially purified antibody which specifically binds to an extracellular domain of the amino acid sequence of SEQ ID NO:3, wherein the antibody is a humanized antibody.

44. (previously presented) The antibody of claim 36 which is a human antibody.

45. (previously presented) The antibody of claim 36 which is conjugated to a therapeutic moiety.

**Attorney Docket Number: MBIO1999-057CP2RC Serial Number: 09/503,387**

46. (previously presented) The antibody of claim 36 which is linked to a detectable substance.

47. (previously presented) The antibody of claim 46, wherein the detectable substance is selected from the group consisting of an enzyme, a prosthetic group, a fluorescent material, a luminescent material, a bioluminescent material, and a radioactive material.

48-52 (canceled)

53. (previously presented) A kit comprising an antibody or fragment thereof as in claim 34, and instructions for use.

54. (previously presented) A kit comprising an antibody or fragment thereof as in claim 46, and instructions for use.

55-64 (canceled)

65. (previously presented) A method of making an antibody that specifically recognizes GPVI, the method comprising:

a) immunizing a mammal with a polypeptide comprising the amino acid sequence of SEQ ID NO:3, the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207180; and

b) collecting a sample from the mammal that contains an antibody that specifically recognizes GPVI.

66. (previously presented) The method of claim 65 wherein the polypeptide is recombinantly produced.



**Attorney Docket Number: MBIO1999-057CP2RCEM      Serial Number: 09/503,387**

67. (previously presented) The method of claim 65 which further comprises purifying antibodies from the sample.

68. (previously presented) The method of claim 65 which further comprises isolating a monoclonal antibody-producing cell from the mammal.

69. (previously presented) The method of claim 68 which further comprises collecting monoclonal antibodies which specifically recognize GPVI from the monoclonal antibody-producing cell.

70. (previously presented) The method of claim 65 wherein the antibody specifically binds to an extracellular domain of the amino acid sequence of SEQ ID NO:3.

71. (previously presented) A monoclonal antibody or fragment thereof which specifically binds to a polypeptide of the amino acid sequence of SEQ ID NO:3, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number 207180, wherein the antibody is a human, humanized or chimeric antibody.

72. (previously presented) The antibody of claim 71 which is conjugated to a therapeutic moiety.

73. (previously presented) The antibody of claim 71 which is linked to a detectable substance.

74. (amended) [The antibody of claim 73,] A monoclonal antibody or fragment thereof which is linked to a detectable substance [is] selected from the group consisting of an enzyme, a prosthetic group, a fluorescent material, a luminescent material, a bioluminescent material, and a radioactive material, and which specifically binds to:

\_\_\_\_\_ a) \_\_\_\_\_ a polypeptide of the amino acid sequence of SEQ ID NO:3; or

(Page 11 of 25)

Attorney Docket Number: MBIO1999-057CP2RCEM Serial Number: 09/503,387

b) the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number 207180,  
wherein the antibody is a human, humanized or chimeric antibody.

75. (previously presented) A kit comprising an antibody or fragment thereof as in claim 26, 87, 88, 89 or 90, and instructions for use.

76. (previously presented) A kit comprising an antibody or fragment thereof as in claim 27, and instructions for use.

77. (previously presented) A kit comprising an antibody or fragment thereof as in claim 29, and instructions for use.

78. (amended) A kit comprising a monoclonal antibody or fragment thereof which specifically binds to a polypeptide of the amino acid sequence of SEQ ID NO:3, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number 207180, wherein the antibody is a human, humanized or chimeric antibody [an antibody or fragment thereof as in claim 71], and instructions for use.

79. (amended) A kit comprising [an antibody or fragment thereof as in claim 73] a monoclonal antibody or fragment thereof which is linked to a detectable substance, and which specifically binds to:

a) a polypeptide of the amino acid sequence of SEQ ID NO:3; or  
b) the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number 207180,  
wherein the antibody is a human, humanized or chimeric antibody, and instructions for use.

80-86 (canceled)

(Page 12 of 25)

Attorney Docket Number: MBIO1999-057CP2RCEM Serial Number: 09/503,387

87. (previously presented) The substantially purified non-human antibody of claim 26, wherein said antibody is at least 80% pure.

88. (previously presented) The substantially purified non-human antibody of claim 87, wherein said antibody is at least 90% pure.

89. (previously presented) The substantially purified non-human antibody of claim 88, wherein said antibody is at least 95% pure.

90. (previously presented) The substantially purified non-human antibody of claim 89, wherein said antibody is at least 99% pure.